Many Americans were introduced to the concept of immunotherapy when former President Jimmy Carter was successfully treated for brain cancer, ninety years . This innovative approach to cancer therapy mobilizes the patient’s immune system to kill tumors in your body. Immunotherapy is in its infancy, and its success depends on increasing scientific understanding of the human genome.
scientist Eduard Porta-Pardo, Ph.D. He is the lead author of a study published recently in the journal Cancer Research Immunology . The study was conducted by the Sanford Burnham Medical Prebys Discovery Center (PAS). Researchers have identified more than 100 previously unknown genetic regions that affect the body’s immune response to malignancy. Dr. Porta-Pardo explains:
By analyzing a large public genome database, we found 122 drivers of the potential immune response – regions where genetic mutations correlate with the presence or absence of immune cells infiltrating tumors. While several of these correspond to proteins with known functions in the immune response, many others offer new directions for cancer immunology research, which could point to new targets for immunotherapy.
With immunotherapy, it is possible to treat even tumors that have metastasized to other organs. Various immunotherapy drugs currently in use have shown remarkable success dramatically reduce or eliminate cancerous tumors, and in some cases preventing a recurrence.
The mechanism used by immunotherapies is helping the immune system to recognize the cancer as a threat, and allowing tumor infiltration by immune cells. In many cases, tumors “hide” the immune system, or block entry of immune cells in tumor way scientists do not yet understand.
The lead author is Adam Godzik, Ph.D., professor and director of the Program for Bioinformatics and Structural Biology. He says:
To develop immunotherapies that are relevant to a wide range of cancers, we need to know much more about how the immune system interacts with tumors. Our study offers many potential new customers for this effort.
This paper emphasizes the value of open data, and we could have access to genomic data from more than 5,000 samples of tumors Cancer Genome Atlas (TCGA), we could jump directly to analysis without having to set up a large collaborative network to collect and sequence as many samples.
Our plan for the next phase of this research is the use of this algorithm for finding genetic regions that correlate with the levels of specific types of immune cells within the tumor, which will reveal more details of immunology Cancer.
Dr. Porta-Pardo added:
We are exploring cancer mutations in the fine resolution to take into account the fact that mutations can affect protein encoded differently depending on where the resulting change, Our algorithm, domainXplorer identifies correlations between phenotype, in this case the amount of immune cells in the tumor, and mutations in the domains of individual proteins -. parts of a protein with different functions
After generations of cancer treatment with chemicals that damage healthy tissue and attacking tumors, and weaken the patient’s immune system so that your body can not defend independently, it may be that medicine has found a new way forward.